North American Menopause Society (NAMS)
Menopause Certification Examination –
Practice Exam 2 Questions and Answers with
Rationales Latest Version Top Rated
Question 1
A 52-year-old woman experienced menopause 18 months ago. She reports moderate-to-severe
hot flashes occurring 10 times daily that significantly impair her work performance. She has no
history of breast cancer, venous thromboembolism (VTE), stroke, coronary artery disease, or
liver disease. Her uterus is intact.
Which treatment is considered the most effective first-line therapy?
A. Paroxetine
B. Gabapentin
C. Systemic estrogen plus progestogen therapy
D. Vaginal estrogen
Correct Answer:
✅ C. Systemic estrogen plus progestogen therapy
Rationale
Systemic menopausal hormone therapy (MHT) remains the gold standard for treating moderate-
to-severe vasomotor symptoms in healthy women younger than 60 years or within 10 years of
menopause onset who have no contraindications.
Because this patient has an intact uterus, estrogen alone would increase the risk of endometrial
hyperplasia and cancer. Therefore, a progestogen must be added for endometrial protection.
Benefits include:
• Approximately 75–90% reduction in hot flashes
, • Improved sleep
• Better quality of life
• Prevention of bone loss
Why the others are incorrect:
• A. Paroxetine: Effective but less effective than hormone therapy.
• B. Gabapentin: Helpful, particularly for nighttime symptoms, but not first-line when
hormone therapy is appropriate.
• D. Vaginal estrogen: Treats genitourinary symptoms only and does not relieve hot
flashes.
Clinical Pearl
Hormone therapy is the most effective treatment for vasomotor symptoms in appropriate
candidates.
Question 2
Which symptom is least likely to be directly caused by estrogen deficiency?
A. Vaginal dryness
B. Hot flashes
C. Dyspareunia
D. Hyperthyroidism
Correct Answer:
✅ D. Hyperthyroidism
Rationale
Estrogen deficiency contributes to many menopausal symptoms but does not cause thyroid
disease.
Common estrogen deficiency manifestations include:
• Vasomotor symptoms
• Night sweats
• Vaginal dryness
, • Dyspareunia
• Recurrent urinary tract infections
• Mood changes
• Sleep disturbances
• Bone loss
Hyperthyroidism results from excess thyroid hormone production and has a completely different
pathophysiology.
Question 3
Which neurotransmitter plays the greatest role in the development of menopausal hot flashes?
A. Dopamine
B. Acetylcholine
C. Norepinephrine
D. Histamine
Correct Answer:
✅ C. Norepinephrine
Rationale
Declining estrogen narrows the hypothalamic thermoneutral zone.
This results in increased activity of:
• Norepinephrine
• Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
Even very small increases in body temperature trigger:
• Sweating
• Vasodilation
• Heat sensation
Recent therapies targeting neurokinin-3 receptors directly address this pathway.
, Question 4
A woman asks whether oral or transdermal estrogen carries the lowest risk of venous
thromboembolism.
Which is the best response?
A. Oral estrogen has the lowest VTE risk.
B. Transdermal estrogen appears to have a lower VTE risk.
C. Both have identical VTE risk.
D. Neither affects clotting.
Correct Answer:
✅ B. Transdermal estrogen appears to have a lower VTE risk.
Rationale
Oral estrogen undergoes first-pass hepatic metabolism, increasing hepatic production of clotting
factors.
Transdermal estrogen:
• Bypasses first-pass liver metabolism
• Produces less activation of coagulation factors
• Appears associated with lower VTE risk in observational studies
This route is often preferred for women with:
• Obesity
• Diabetes
• Hypertension
• Elevated triglycerides
• Increased thrombotic risk
Question 5
Which patient has the strongest contraindication to systemic hormone therapy?
A. Controlled hypertension
Menopause Certification Examination –
Practice Exam 2 Questions and Answers with
Rationales Latest Version Top Rated
Question 1
A 52-year-old woman experienced menopause 18 months ago. She reports moderate-to-severe
hot flashes occurring 10 times daily that significantly impair her work performance. She has no
history of breast cancer, venous thromboembolism (VTE), stroke, coronary artery disease, or
liver disease. Her uterus is intact.
Which treatment is considered the most effective first-line therapy?
A. Paroxetine
B. Gabapentin
C. Systemic estrogen plus progestogen therapy
D. Vaginal estrogen
Correct Answer:
✅ C. Systemic estrogen plus progestogen therapy
Rationale
Systemic menopausal hormone therapy (MHT) remains the gold standard for treating moderate-
to-severe vasomotor symptoms in healthy women younger than 60 years or within 10 years of
menopause onset who have no contraindications.
Because this patient has an intact uterus, estrogen alone would increase the risk of endometrial
hyperplasia and cancer. Therefore, a progestogen must be added for endometrial protection.
Benefits include:
• Approximately 75–90% reduction in hot flashes
, • Improved sleep
• Better quality of life
• Prevention of bone loss
Why the others are incorrect:
• A. Paroxetine: Effective but less effective than hormone therapy.
• B. Gabapentin: Helpful, particularly for nighttime symptoms, but not first-line when
hormone therapy is appropriate.
• D. Vaginal estrogen: Treats genitourinary symptoms only and does not relieve hot
flashes.
Clinical Pearl
Hormone therapy is the most effective treatment for vasomotor symptoms in appropriate
candidates.
Question 2
Which symptom is least likely to be directly caused by estrogen deficiency?
A. Vaginal dryness
B. Hot flashes
C. Dyspareunia
D. Hyperthyroidism
Correct Answer:
✅ D. Hyperthyroidism
Rationale
Estrogen deficiency contributes to many menopausal symptoms but does not cause thyroid
disease.
Common estrogen deficiency manifestations include:
• Vasomotor symptoms
• Night sweats
• Vaginal dryness
, • Dyspareunia
• Recurrent urinary tract infections
• Mood changes
• Sleep disturbances
• Bone loss
Hyperthyroidism results from excess thyroid hormone production and has a completely different
pathophysiology.
Question 3
Which neurotransmitter plays the greatest role in the development of menopausal hot flashes?
A. Dopamine
B. Acetylcholine
C. Norepinephrine
D. Histamine
Correct Answer:
✅ C. Norepinephrine
Rationale
Declining estrogen narrows the hypothalamic thermoneutral zone.
This results in increased activity of:
• Norepinephrine
• Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
Even very small increases in body temperature trigger:
• Sweating
• Vasodilation
• Heat sensation
Recent therapies targeting neurokinin-3 receptors directly address this pathway.
, Question 4
A woman asks whether oral or transdermal estrogen carries the lowest risk of venous
thromboembolism.
Which is the best response?
A. Oral estrogen has the lowest VTE risk.
B. Transdermal estrogen appears to have a lower VTE risk.
C. Both have identical VTE risk.
D. Neither affects clotting.
Correct Answer:
✅ B. Transdermal estrogen appears to have a lower VTE risk.
Rationale
Oral estrogen undergoes first-pass hepatic metabolism, increasing hepatic production of clotting
factors.
Transdermal estrogen:
• Bypasses first-pass liver metabolism
• Produces less activation of coagulation factors
• Appears associated with lower VTE risk in observational studies
This route is often preferred for women with:
• Obesity
• Diabetes
• Hypertension
• Elevated triglycerides
• Increased thrombotic risk
Question 5
Which patient has the strongest contraindication to systemic hormone therapy?
A. Controlled hypertension
